Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 0.62%.

  • Viridian Therapeutics, Inc.\DE's Return on Capital Employed fell 1800.0% to 0.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.62%, marking a year-over-year decrease of 1800.0%. This contributed to the annual value of 0.53% for FY2024, which is 600.0% up from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Return on Capital Employed is 0.62%, which was down 1800.0% from 0.65% recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Return on Capital Employed's 5-year high stood at 0.33% during Q4 2022, with a 5-year trough of 1.28% in Q2 2021.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.5% (2025), whereas its average is 0.61%.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Return on Capital Employed surged by 11500bps in 2021 and then crashed by -3300bps in 2023.
  • Viridian Therapeutics, Inc.\DE's Return on Capital Employed (Quarter) stood at 0.4% in 2021, then grew by 17bps to 0.33% in 2022, then tumbled by -100bps to 0.66% in 2023, then soared by 37bps to 0.42% in 2024, then tumbled by -47bps to 0.62% in 2025.
  • Its Return on Capital Employed stands at 0.62% for Q3 2025, versus 0.65% for Q2 2025 and 0.5% for Q1 2025.